BMS at ACR Convergence 2020

Intended for U.S. scientific audiences only.

The American College of Rheumatology (ACR) Convergence 2020 is an important opportunity to review and share the latest breakthroughs and research for patients living with rheumatic diseases. At this year’s meeting, we are presenting data on three assets spanning four disease areas, including rheumatoid arthritis, juvenile idiopathic arthritis, lupus and psoriatic arthritis. 

In the face of unprecedented challenges over the past year, we’ve remained steadfast in our dedication to the rheumatology community and look forward to showcasing research that has the potential to positively impact people living with immune-mediated diseases.

Hear from Samit Hirawat, M.D., executive vice president, chief medical officer, Global Drug Development, about Bristol Myers Squibb’s presence at the American College of Rheumatology (ACR) Convergence, underscoring our enduring commitment to patients living with immune-mediated diseases.

Our Science   

Our diverse, promising pipeline and research on currently available therapies are driven by our focus on offering innovative medicines that transform patients’ lives. Read about how our scientists are addressing some of the most challenging diseases of our time and advancing research across numerous immune-mediated diseases.

Lupus: Treatments, Research and Bristol Myers Squibb’s Dedication to Patients – A Q&A with Subhashis Banerjee >

Subhashis Banerjee, vice president & disease area head, Rheumatology and Dermatology, explains how we are leaving no stone unturned in our approach to lupus research. 

Pursuing Innovative Approaches to Advance Research for Psoriatic Disease >

Shalabh Singhal, executive director, development program lead, Rheumatology, explains how by targeting the tyrosine kinase 2 (TYK2) pathway, researchers can further our understanding of how to improve care for psoriatic disease.

Destination: The Impact of Precision Medicine in Disease Management for People With Immune-Mediated Diseases >

Brian Gavin, development lead, discusses precision medicine for immune-mediated diseases, including rheumatoid arthritis and systemic lupus erythematosus.

Our Precision-Focused Approach in Rheumatoid Arthritis and Beyond: A Q&A With Dr. Sean E. Connolly >

Sean E. Connolly, executive director, head of Clinical Evaluation and Collaborations, explains our precision medicine research approach and shares a video on the potential role of biomarkers.


Our research in Immunology and Rheumatology spans a number of diseases and pathways of focus. Learn more below.

TYK2 Pathway Fact Sheet >

Learn about the scientific mechanism behind the TYK2 pathway and its role in immune-mediated diseases.

Psoriatic Arthritis Infographic >

Learn more about psoriatic arthritis, its symptoms and its potential impact on patients. 

Rheumatoid Arthritis Infographic >

Learn more about rheumatoid arthritis, an immune-mediated disease that affects patients worldwide.

Juvenile Idiopathic Arthritis (JIA) Infographic >

Learn more about JIA, its symptoms and effects on pediatric patients worldwide.

Lupus Infographic >

Learn more about systemic lupus erythematosus (SLE) and how it can impact patients around the world.